Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Connecticut
About this trial
The investigators will conduct an optimization trial among N=256 PWID newly started on medication for opioid use disorder and Pre-Exposure Prophylaxis (PrEP) to assess the performance of four intervention components (Attention, Executive Functioning, Memory, and Information Processing) aimed at enhancing the ability of PWID on MOUD to process and utilize HIV prevention content, leading to improvements in HIV prevention information, motivation, behavioral skills, and behaviors (IMB).
Eligibility criteria
Qualifiers
being 18 years or older
meeting DSM-V criteria for opioid dependence and being newly prescribed and adherent to Medication for Opioid Use Disorder (e.g., methadone, buprenorphine) at the APT Foundation, Inc.
showing mild cognitive impairment based on the Montreal Cognitive Assessment (MoCA) screening
having initiated Pre-Exposure Prophylaxis (PrEP) within the past week
Disqualifiers
unable to provide consent
actively suicidal
actively homicidal
actively psychotic
Trial design
Treatments tested in this trial
- community-friendly health recovery program
- Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Treatment groups
256 Participants
are divided into 16 treatment groups16
Treatment groupsSee each treatment group below.
Locations
1APT Foundation06519, New HavenConnecticut, United States
Sponsors and collaborators
University of Connecticut
Lead sponsor
Source ClinicalTrials.gov